At Sandoz, our purpose is to pioneer access for patients. Our business ambition is to be the world’s leading and most valued generics company.
Our global portfolio comprises approximately 1 000 molecules, covering all a wide range of major therapeutic areas, which accounted for 2021 sales of USD 9.6 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach approximately 500 million patients every year. Our broad portfolio is spearheaded by our global leadership positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems.
